A Phase 3 interventional study of Vortioxetine 10 mg/day and Vortioxetine 20 mg/day in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 98 sites in 19 countries. Open to participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-09-22.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 33rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 7 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 683 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 4th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 3, and was the 26th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vortioxetine 10 mg/day
Drug: Vortioxetine 20 mg/day
A decision has been taken to stop recruitment into this treatment arm.
Drug: Fluoxetine 20mg/day
Other: Placebo
Drug page: Vortioxetine
10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Also known as: Brintellix ®, Lu AA21004
Drug page: Vortioxetine
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Also known as: Brintellix ®, Lu AA21004
Drug page: Fluoxetine
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Encapsulated tablet, orally
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.
Time frame: Baseline (Week 4 of Phase A), Week 8 of Phase B
Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B
Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Response
CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline \[Randomization\])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Remission
CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Parent Global Assessment (PGA) Score
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
Time frame: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Clinical Global Impression - Global Improvement (CGI-I) Score
The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Percentage of Participants With CGI-S Remission
CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
This study included 2 periods: single-blind (SB) (treatment with standardized brief psychosocial intervention \[BPI\] and placebo) and double-blind (DB) (treatment with BPI and placebo, vortioxetine 10 milligrams \[mg\]/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day).
| Milestone | Single-Blind: Placebo | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|---|
| Started | 683 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 677 | 0 | 0 | 0 | 0 |
| Completed | 540 | 0 | 0 | 0 | 0 |
| Not completed | 143 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 85 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified | 20 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 6 | 0 | 0 | 0 | 0 |
| Milestone | Single-Blind: Placebo | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|---|
| Started | 0 | 153 | 151 | 153 | 83 |
| Received at least 1 dose of study drug | 0 | 153 | 151 | 153 | 83 |
| Full analysis set (fas) | 0 | 153 | 148 | 148 | 81 |
| Completed | 0 | 138 | 135 | 133 | 78 |
| Not completed | 0 | 15 | 16 | 20 | 5 |
| Withdrew: Adverse event | 0 | 1 | 2 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 3 | 6 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 4 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Other than specified | 0 | 5 | 7 | 5 | 2 |
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg | Vortioxetine Average (Avg. VOR) |
|---|---|---|---|---|---|
| Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B | -17.48 ± 1.35 | -19.20 ± 1.37 | -19.94 ± 1.37 | -20.78 ± 1.60 | -19.57 ± 1.16 |
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 2 | -9.20 ± 1.17 | -9.54 ± 1.18 | -10.30 ± 1.19 | -10.17 ± 1.32 |
| Change at Week 4 | -13.15 ± 1.28 | -14.56 ± 1.30 | -15.62 ± 1.30 | -13.97 ± 1.50 |
| Change at Week 6 | -16.00 ± 1.32 | -17.64 ± 1.34 | -18.28 ± 1.34 | -17.75 ± 1.56 |
The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Mood Score: Change at Week 2 | -2.82 ± 0.40 | -3.10 ± 0.40 | -3.47 ± 0.40 | -3.02 ± 0.45 |
| Mood Score: Change at Week 4 | -3.69 ± 0.42 | -4.39 ± 0.43 | -4.77 ± 0.43 | -3.73 ± 0.49 |
| Mood Score: Change at Week 6 | -4.67 ± 0.43 | -5.39 ± 0.44 | -5.52 ± 0.44 | -4.97 ± 0.51 |
| Mood Score: Change at Week 8 | -5.08 ± 0.44 | -5.64 ± 0.44 | -5.95 ± 0.45 | -5.84 ± 0.51 |
| Somatic Score: Change at Week 2 | -2.81 ± 0.44 | -2.61 ± 0.44 | -2.88 ± 0.44 | -3.02 ± 0.50 |
| Somatic Score: Change at Week 4 | -4.08 ± 0.47 | -4.30 ± 0.48 | -4.70 ± 0.48 | -4.26 ± 0.56 |
| Somatic Score: Change at Week 6 | -4.86 ± 0.48 | -5.53 ± 0.49 | -5.33 ± 0.49 | -5.57 ± 0.57 |
| Somatic Score: Change at Week 8 | -5.38 ± 0.49 | -6.15 ± 0.50 | -6.08 ± 0.50 | -6.44 ± 0.57 |
| Subjective Score: Change at Week 2 | -1.44 ± 0.22 | -1.46 ± 0.22 | -1.43 ± 0.22 | -1.56 ± 0.25 |
| Subjective Score: Change at Week 4 | -2.04 ± 0.23 | -2.12 ± 0.23 | -2.20 ± 0.23 | -2.17 ± 0.27 |
| Subjective Score: Change at Week 6 | -2.43 ± 0.24 | -2.42 ± 0.24 | -2.65 ± 0.24 | -2.38 ± 0.28 |
| Subjective Score: Change at Week 8 | -2.56 ± 0.24 | -2.59 ± 0.24 | -2.84 ± 0.24 | -2.65 ± 0.28 |
| Behaviour Score: Change at Week 2 | -2.16 ± 0.34 | -2.40 ± 0.34 | -2.56 ± 0.35 | -2.61 ± 0.39 |
| Behaviour Score: Change at Week 4 | -3.39 ± 0.38 | -3.77 ± 0.39 | -4.00 ± 0.39 | -3.80 ± 0.45 |
| Behaviour Score: Change at Week 6 | -4.09 ± 0.39 | -4.31 ± 0.39 | -4.83 ± 0.40 | -4.80 ± 0.46 |
| Behaviour Score: Change at Week 8 | -4.47 ± 0.40 | -4.80 ± 0.41 | -5.09 ± 0.41 | -5.83 ± 0.48 |
CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline \[Randomization\])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
| percentage of participants | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Week 2 | 7.8 | 10.2 | 11.6 | 16.3 |
| Week 4 | 20.7 | 23.4 | 26.6 | 26.9 |
| Week 6 | 30.8 | 31.6 | 37.2 | 33.3 |
| Week 8 | 29.4 | 36.4 | 41.0 | 47.4 |
CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
| percentage of participants | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Week 2 | 2.0 | 5.4 | 2.7 | 3.8 |
| Week 4 | 9.0 | 9.5 | 10.1 | 9.0 |
| Week 6 | 14.7 | 15.4 | 15.3 | 14.1 |
| Week 8 | 14.7 | 16.7 | 20.1 | 26.9 |
The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| PGBI: Change at Week 2 | -3.33 ± 0.55 | -3.38 ± 0.55 | -3.78 ± 0.56 | -3.78 ± 0.63 |
| PGBI: Change at Week 4 | -4.11 ± 0.58 | -4.72 ± 0.59 | -5.33 ± 0.59 | -4.45 ± 0.68 |
| PGBI: Change at Week 6 | -5.32 ± 0.58 | -5.58 ± 0.59 | -5.82 ± 0.59 | -6.05 ± 0.68 |
| PGBI: Change at Week 8 | -5.81 ± 0.61 | -6.51 ± 0.62 | -6.46 ± 0.62 | -6.56 ± 0.72 |
| CGBI: Change at Week 2 | -2.66 ± 0.61 | -3.32 ± 0.61 | -3.27 ± 0.61 | -2.94 ± 0.70 |
| CGBI: Change at Week 4 | -3.65 ± 0.65 | -4.15 ± 0.65 | -4.16 ± 0.65 | -3.16 ± 0.76 |
| CGBI: Change at Week 6 | -4.62 ± 0.63 | -5.43 ± 0.64 | -5.17 ± 0.63 | -5.14 ± 0.73 |
| CGBI: Change at Week 8 | -5.26 ± 0.65 | -6.12 ± 0.66 | -5.48 ± 0.65 | -5.46 ± 0.76 |
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Week 2 | 3.31 ± 0.09 | 3.25 ± 0.09 | 3.18 ± 0.09 | 3.13 ± 0.11 |
| Week 4 | 2.97 ± 0.10 | 2.90 ± 0.10 | 2.84 ± 0.10 | 2.90 ± 0.12 |
| Week 6 | 2.73 ± 0.10 | 2.73 ± 0.10 | 2.68 ± 0.10 | 2.80 ± 0.12 |
| Week 8 | 2.68 ± 0.11 | 2.62 ± 0.11 | 2.61 ± 0.11 | 2.59 ± 0.13 |
The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 1 | -0.25 ± 0.07 | -0.27 ± 0.07 | -0.28 ± 0.07 | -0.22 ± 0.08 |
| Change at Week 2 | -0.50 ± 0.08 | -0.60 ± 0.08 | -0.65 ± 0.08 | -0.63 ± 0.10 |
| Change at Week 3 | -0.67 ± 0.08 | -0.62 ± 0.08 | -0.79 ± 0.08 | -0.77 ± 0.10 |
| Change at Week 4 | -0.95 ± 0.09 | -1.00 ± 0.09 | -1.06 ± 0.09 | -1.01 ± 0.12 |
| Change at Week 6 | -1.13 ± 0.10 | -1.22 ± 0.10 | -1.27 ± 0.10 | -1.23 ± 0.12 |
| Change at Week 8 | -1.31 ± 0.10 | -1.40 ± 0.11 | -1.44 ± 0.11 | -1.57 ± 0.13 |
The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Week 1 | 3.66 ± 0.07 | 3.63 ± 0.07 | 3.60 ± 0.07 | 3.72 ± 0.08 |
| Week 2 | 3.32 ± 0.08 | 3.30 ± 0.08 | 3.19 ± 0.08 | 3.26 ± 0.10 |
| Week 3 | 3.20 ± 0.08 | 3.20 ± 0.08 | 3.14 ± 0.08 | 3.23 ± 0.10 |
| Week 4 | 2.93 ± 0.09 | 2.93 ± 0.09 | 2.82 ± 0.09 | 2.97 ± 0.11 |
| Week 6 | 2.70 ± 0.09 | 2.64 ± 0.10 | 2.65 ± 0.10 | 2.78 ± 0.12 |
| Week 8 | 2.69 ± 0.10 | 2.58 ± 0.08 | 2.60 ± 0.10 | 2.57 ± 0.12 |
CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
| percentage of participants | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Week 1 | 0 | 0.7 | 0 | 0 |
| Week 2 | 0.7 | 3.4 | 1.4 | 3.7 |
| Week 3 | 3.3 | 4.1 | 4.7 | 7.4 |
| Week 4 | 8.5 | 8.1 | 12.8 | 12.3 |
| Week 6 | 14.4 | 16.2 | 16.2 | 14.8 |
| Week 8 | 22.9 | 22.3 | 20.9 | 29.6 |
The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | 8.93 ± 1.23 | 9.84 ± 1.25 | 8.73 ± 1.26 | 10.54 ± 1.39 |
| Change at Week 8 | 12.71 ± 1.31 | 12.98 ± 1.33 | 13.22 ± 1.34 | 16.35 ± 1.51 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.48 ± 0.27 | -0.51 ± 0.27 | -0.48 ± 0.27 | -0.41 ± 0.31 |
| Change at Week 8 | -0.73 ± 0.26 | -1.07 ± 0.27 | -1.01 ± 0.27 | -1.08 ± 0.29 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -1.20 ± 0.31 | -1.65 ± 0.31 | -1.78 ± 0.31 | -1.42 ± 0.35 |
| Change at Week 8 | -1.72 ± 0.32 | -2.23 ± 0.32 | -2.05 ± 0.32 | -2.31 ± 0.36 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.98 ± 0.30 | -1.36 ± 0.31 | -1.33 ± 0.31 | -1.22 ± 0.35 |
| Change at Week 8 | -1.24 ± 0.31 | -1.98 ± 0.32 | -1.36 ± 0.32 | -1.67 ± 0.36 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.63 ± 0.31 | -1.48 ± 0.32 | -1.21 ± 0.32 | -1.27 ± 0.36 |
| Change at Week 8 | -1.08 ± 0.32 | -1.82 ± 0.33 | -1.45 ± 0.33 | -1.41 ± 0.36 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -1.22 ± 0.34 | -1.19 ± 0.35 | -1.63 ± 0.35 | -0.94 ± 0.39 |
| Change at Week 8 | -1.39 ± 0.36 | -1.32 ± 0.37 | -1.74 ± 0.37 | -1.73 ± 0.41 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.22 ± 0.28 | -0.81 ± 0.28 | -0.45 ± 0.28 | -0.50 ± 0.32 |
| Change at Week 8 | -0.70 ± 0.28 | -0.79 ± 0.28 | -1.02 ± 0.28 | -0.69 ± 0.32 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.81 ± 0.19 | -1.19 ± 0.19 | -1.17 ± 0.20 | -1.01 ± 0.22 |
| Change at Week 8 | -1.17 ± 0.20 | -1.55 ± 0.20 | -1.47 ± 0.20 | -1.54 ± 0.23 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.84 ± 0.21 | -1.28 ± 0.21 | -1.22 ± 0.22 | -1.13 ± 0.24 |
| Change at Week 8 | -1.22 ± 0.22 | -1.80 ± 0.22 | -1.51 ± 0.22 | -1.66 ± 0.25 |
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | 3.94 ± 0.95 | 4.90 ± 0.96 | 4.90 ± 0.97 | 4.36 ± 1.09 |
| Change at Week 8 | 6.22 ± 0.98 | 7.08 ± 0.99 | 7.14 ± 1.00 | 6.79 ± 1.12 |
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
| units on a scale | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|
| Change at Week 4 | 0.28 ± 0.09 | 0.37 ± 0.09 | 0.43 ± 0.09 | 0.24 ± 0.11 |
| Change at Week 8 | 0.41 ± 0.09 | 0.49 ± 0.09 | 0.52 ± 0.09 | 0.45 ± 0.11 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-Blind: Placebo | 0/677 (0%) | 6/677 (0.9%) | 106/677 (15.7%) |
| Double-Blind: Placebo | 0/153 (0%) | 3/153 (2%) | 45/153 (29.4%) |
| Double-Blind: Vortioxetine 10 mg | 0/151 (0%) | 1/151 (0.7%) | 55/151 (36.4%) |
| Double-Blind: Vortioxetine 20 mg | 0/153 (0%) | 2/153 (1.3%) | 42/153 (27.5%) |
| Double-Blind: Fluoxetine 20 mg | 0/83 (0%) | 1/83 (1.2%) | 27/83 (32.5%) |
| Event | Single-Blind: Placebo | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|---|
| Forearm fractureInjury, poisoning and procedural complications | 0/677 | 0/153 | 0/151 | 0/153 | 1/83 |
| TracheitisInfections and infestations | 0/677 | 0/153 | 1/151 | 0/153 | 0/83 |
| Suicide attemptPsychiatric disorders | 1/677 | 1/153 | 0/151 | 0/153 | 0/83 |
| CellulitisInfections and infestations | 0/677 | 1/153 | 0/151 | 0/153 | 0/83 |
| PneumoniaInfections and infestations | 0/677 | 1/153 | 0/151 | 0/153 | 0/83 |
| Major depressionPsychiatric disorders | 0/677 | 0/153 | 0/151 | 1/153 | 0/83 |
| ManiaPsychiatric disorders | 0/677 | 0/153 | 0/151 | 1/153 | 0/83 |
| TachycardiaCardiac disorders | 1/677 | 0/153 | 0/151 | 0/153 | 0/83 |
| GastroenteritisInfections and infestations | 1/677 | 0/153 | 0/151 | 0/153 | 0/83 |
| Viral pharyngitisInfections and infestations | 1/677 | 0/153 | 0/151 | 0/153 | 0/83 |
| Event | Single-Blind: Placebo | Double-Blind: Placebo | Double-Blind: Vortioxetine 10 mg | Double-Blind: Vortioxetine 20 mg | Double-Blind: Fluoxetine 20 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 23/677 | 7/153 | 19/151 | 17/153 | 5/83 |
| HeadacheNervous system disorders | 39/677 | 17/153 | 14/151 | 14/153 | 4/83 |
| VomitingGastrointestinal disorders | 13/677 | 3/153 | 14/151 | 10/153 | 3/83 |
| Abdominal painGastrointestinal disorders | 9/677 | 2/153 | 9/151 | 6/153 | 2/83 |
| DizzinessNervous system disorders | 9/677 | 5/153 | 7/151 | 5/153 | 3/83 |
| NasopharyngitisInfections and infestations | 13/677 | 5/153 | 6/151 | 4/153 | 3/83 |
| Abdominal pain upperGastrointestinal disorders | 15/677 | 4/153 | 4/151 | 3/153 | 3/83 |
| DiarrhoeaGastrointestinal disorders | 9/677 | 4/153 | 5/151 | 1/153 | 3/83 |
| Decreased appetiteMetabolism and nutrition disorders | 0/677 | 2/153 | 1/151 | 2/153 | 3/83 |
| IllnessGeneral disorders | 0/677 | 0/153 | 0/151 | 5/153 | 0/83 |
All-patients-treated set Phase A (APTS_A) included all participants enrolled to the 4-week Single-blind period (Phase A) who received at least 1 dose of study drug.
| Age, Continuous(years) | Single-Blind: Placebo |
|---|---|
| Mean | 9.3 ± 1.42 |
| Sex: Female, Male(Participants) | Single-Blind: Placebo |
|---|---|
| Female | 312 |
| Male | 365 |
| Race/Ethnicity, Customized(Participants) | Single-Blind: Placebo |
|---|---|
| Race — American Indian or Alaska Native | 1 |
| Race — Asian | 2 |
| Race — Black or African American | 112 |
| Race — Not Reported | 12 |
| Race — Other | 229 |
| Race — White | 321 |
| Children Depression Rating Scale - Revised (CDRS-R) Total Score(units on a scale) | Single-Blind: Placebo |
|---|---|
| Mean | 63.4 ± 9.12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Jan 2022, 68 months.
Results were first posted in Sep 2022, 8 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 68 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine